Intensive Urate Lowering in Diabetic Kidney Disease

Restricted access

An intensive urate-lowering strategy consisting of verinurad and febuxostat reduces albuminuria in patients with type 2 diabetes and hyperuricemia, reports a phase 2 trial in the American Journal of Kidney Diseases.

The multicenter trial enrolled 60 adult patients with type 2 diabetes; albuminuria, urine albumin-to-creatinine ratio (UACR) 30 to 3500 mg/g; and hyperuricemia, serum urate (sUA) concentration 6.0 mg/dL or greater. Mean age was 61.5 years, 70% of patients were men, and about one-half had an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2. The study excluded patients with stage 4 or 5 chronic